NCI Objects To Fisher As Scientific Director Of NSABP, Threatens To Cut Off Funding
In Brief: Senate Cancer Coalition Hearing On Tamoxifin Planned for May 11; Bresnick Leads AACR
Fisher and Redmond Subject Of Misconduct Investigation; ORI
Herberman Outlines NSABP restructuring In Plan To NCI
DCT Advisors Approve Increased Spending On Trials Monitoring
Possible Breach of Patient Confidentially By Calif. Physician; NCI
Trending Stories
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- NCI releases names of members of ad hoc working group—filling the void left by BSA
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines - NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium